Millendo Therapeutics Receives $62,000,000 Series B Funding

  • Feed Type
  • Date
    1/4/2016
  • Company Name
    Millendo Therapeutics
  • Mailing Address
    301 N. Main St. Ann Arbor, MI 48104 USA
  • Company Description
    Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options.
  • Website
    http://www.millendo.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $62,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    This acquisition of MLE4901 combined with the new funding and our current programs around ATR-101 puts us on a new trajectory to build a specialty pharmaceutical company focused on multiple disease-modifying treatments for endocrine disorders caused by hormone dysregulation.
  • M&A Terms
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    Frazier Healthcare Partners
  • Venture Investor
    Adams Street Partners
  • Venture Investor
    Altitude Life Science Ventures
  • Venture Investor
    Longwood Fund
  • Venture Investor
    Renaissance Venture Capital Fund
  • Venture Investor
    Osage Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
    University of Michigan

Trending on Xconomy